Panacea Biotec hit a lower circuit of 5% at Rs 184.45 after the US drug regulator issued a warning letter to the drug maker's unit in Baddi, Himachal Pradesh.
The United States Food and Drug Administration (USFDA) issued a warning letter to company following its inspection of the company's Baddi plant conducted from 10 to 20 February 2020.
According to a statement published on the website of the US FDA, the warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.
Until you correct all violations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new drug applications or supplements listing your firm as a drug manufacturer, the US drug regulator said.
Panacea Biotec is an innovation-led biotechnology group that focuses on discovery, development, and commercialisation of prescription medicines.
The company reported a net loss of Rs 8.84 crore in Q1 June 2020 as compared with a net loss of Rs 29.21 crore in Q1 June 2019. Net sales jumped 208.10% to Rs 76.48 crore in Q1 June 2020 over Q1 June 2019.
In the past three months, the stock has lost 8.44% while the benchmark S&P BSE Sensex gained 9.37% during the same period.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU